The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. (Q53852790)

21 May 2018

title

The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. (English)

1 reference

21 May 2018

author name string

Moyle G

series ordinal

1

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 March 1998

1 reference

21 May 2018

Expert Opinion on Investigational Drugs

published in

1 reference

21 May 2018

volume

7

1 reference

21 May 2018

issue

3

1 reference

21 May 2018

page(s)

413-426

1 reference

21 May 2018

Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Structural mechanisms of HIV drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Understanding and Improving Patient Compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Strategies for enhancing patient compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

Improved compliance measures: applications in an ambulatory hypertensive drug trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.3.413

21 January 2018

Identifiers

DOI

10.1517/13543784.7.3.413

1 reference

21 May 2018

PubMed ID

15991982

1 reference

21 May 2018